[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495907":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":156,"collaborators":158,"id":178,"slug":179,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":36,"eligibilityCriteria":184,"healthyVolunteers":180,"sex":185,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":36,"studyType":191,"phases":192,"briefSummary":194,"conditions":195,"keywords":36,"overallStatus":73,"whyStopped":36,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},{"fullName":5,"class":6},"Women's Hospital School Of Medicine Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nab-Paclitaxel\u002Fcarboplatin for systemic therapy after surgery","EXPERIMENTAL","Nab-Paclitaxel\u002Fcarboplatin q3 weeks Nab-Paclitaxel 260 mg\u002Fm² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel\u002Fcarboplatin weekly Dose-dense Nab-Paclitaxel 100 mg\u002Fm2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles",[13],"Drug: nab-paclitaxel combined with carboplatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Paclitaxel\u002Fcarboplatin for systemic therapy","ACTIVE_COMPARATOR","Paclitaxel 175 mg\u002Fm² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles\n\nPaclitaxel weekly\u002Fcarboplatin weekly Paclitaxel 60 mg\u002Fm2 followed by carboplatin AUC（area under the curve） 2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","nab-paclitaxel combined with carboplatin","Nab-Paclitaxel\u002Fcarboplatin q3weeks Nab-Paclitaxel 260 mg\u002Fm² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel\u002Fcarboplatin weekly Dose-dense Nab-Paclitaxel 100 mg\u002Fm2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg\u002Fm² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles\n\nPaclitaxel weekly\u002Fcarboplatin weekly Paclitaxel 60 mg\u002Fm2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)",[9,15],[26],"paclitaxel combined with carboplatin",[28],{"name":29,"affiliation":30,"role":31},"Yaxia Chen, MD","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","+86-571-87061501",null,"chenyax@zju.edu.cn",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Yang Li, MD","li_yang@zju.edu.cn",[42,60,71,86,94,102,110,118,129,137,148],{"facility":43,"status":44,"city":45,"state":46,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Sun Yat-Sen University Cancer Hospital","NOT_YET_RECRUITING","Guangzhou","Guangdong","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56,58],{"name":57,"role":34,"phone":36,"phoneExt":36,"email":36},"Yanling Feng",{"name":59,"role":31,"phone":36,"phoneExt":36,"email":36},"Jihong Liu",{"facility":61,"status":44,"city":62,"state":63,"zip":64,"country":47,"countryCode":48,"cosmosGeoPoint":36,"geoPoint":36,"contacts":65},"Qilu Hospital of Shandong University","Ji'nan","Shandong","250012",[66,69],{"name":67,"role":34,"phone":36,"phoneExt":36,"email":68},"Jie Jiang","qljiangjie@aliyun.com",{"name":70,"role":31,"phone":36,"phoneExt":36,"email":36},"Beihua Kong",{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":47,"countryCode":48,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Yaxia Chen","RECRUITING","Hangzhou","Zhejiang","310006",{"type":50,"coordinates":78},[79,80],120.16142,30.29365,{"lat":80,"lon":79},[83,85],{"name":84,"role":34,"phone":35,"phoneExt":36,"email":40},"Yang Li, Doctor",{"name":72,"role":31,"phone":36,"phoneExt":36,"email":36},{"facility":87,"status":44,"city":74,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"Sir Run Run Hospital",{"type":50,"coordinates":89},[79,80],{"lat":80,"lon":79},[92],{"name":93,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianhua Yang",{"facility":95,"status":44,"city":74,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":96,"geoPoint":98,"contacts":99},"The First Affiliated Hospital of Medical College of Zhejiang University",{"type":50,"coordinates":97},[79,80],{"lat":80,"lon":79},[100],{"name":101,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianhua Qian",{"facility":103,"status":44,"city":74,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":104,"geoPoint":106,"contacts":107},"The Second Affiliated Hospital of Medical College of Zhejiang University",{"type":50,"coordinates":105},[79,80],{"lat":80,"lon":79},[108],{"name":109,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianwei Zhou",{"facility":111,"status":44,"city":74,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"Zhejiang Cancer Hospital",{"type":50,"coordinates":113},[79,80],{"lat":80,"lon":79},[116],{"name":117,"role":34,"phone":36,"phoneExt":36,"email":36},"Yaqing Chen",{"facility":119,"status":44,"city":120,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Ningbo women's and children's Hospital","Ningbo",{"type":50,"coordinates":122},[123,124],121.54945,29.87819,{"lat":124,"lon":123},[127],{"name":128,"role":34,"phone":36,"phoneExt":36,"email":36},"Lingjun Zhao",{"facility":130,"status":44,"city":120,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":131,"geoPoint":133,"contacts":134},"The No, 1 People's Hospital of Ningbo",{"type":50,"coordinates":132},[123,124],{"lat":124,"lon":123},[135],{"name":136,"role":34,"phone":36,"phoneExt":36,"email":36},"Yutao Guan",{"facility":138,"status":44,"city":139,"state":75,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"The Second Affiliated Hospital of Wenzhou Medical University","Wenzhou",{"type":50,"coordinates":141},[142,143],120.66682,27.99942,{"lat":143,"lon":142},[146],{"name":147,"role":34,"phone":36,"phoneExt":36,"email":36},"Yan Hu",{"facility":149,"status":44,"city":139,"state":36,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":150,"geoPoint":152,"contacts":153},"The First Affiliated Hospital of Wenzhou Medical University",{"type":50,"coordinates":151},[142,143],{"lat":143,"lon":142},[154],{"name":155,"role":34,"phone":36,"phoneExt":36,"email":36},"Xiaojian Yan",{"type":157,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[159,161,163,165,167,169,171,172,174,176],{"name":160,"class":6},"Jiaxing Maternity and Child Health Care Hospital",{"name":162,"class":6},"Zhejiang University",{"name":164,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":166,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":168,"class":6},"Second Affiliated Hospital of Wenzhou Medical University",{"name":170,"class":6},"Sun Yat-Sen University Cancer Center",{"name":61,"class":6},{"name":173,"class":6},"Ningbo No. 1 Hospital",{"name":175,"class":6},"Ningbo Women & Children's Hospital",{"name":177,"class":6},"Sir Run Run Shaw Hospital","100495907","phase-3-nab-paclitaxel-versus-sb-taxanes-as-first-line-treatment-in-advanced-ovarian-cancer-100495907",false,"NCT05737303","Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Epithelial ovarian cancer\u002Ftubal cancer\u002Fperitoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International Federation of Gynecology and Obstetrics）stage\n2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points\n3. Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment\n4. Written informed consent\n5. Expected survival ≥6 months\n6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1)\n7. Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation.\n\nExclusion Criteria:\n\n1. Patients with low malignant potential ovarian tumors;\n2. Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;\n3. Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;\n4. Patients with central nervous system metastasis or peripheral neuropathy \\> grade 1;\n5. Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;\n6. Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); According to NYHA（New York Heart Association） criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 55% indicated by color Doppler ultrasonography;\n7. Uncontrolled systemic infection requiring anti-infective treatment;\n8. Arteriovenous thrombosis events occurring within 6 months before randomization, such as cardiovascular and cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep vein thrombosis and pulmonary embolism;\n9. Patients who are allergic to the active ingredients or excipients of albumin paclitaxel and carboplatin for injection;\n10. Pregnant or lactating women;\n11. Those who were considered unsuitable for inclusion by the researchers.","FEMALE","18 Years","75 Years",{"count":189,"type":190},538,"ESTIMATED","INTERVENTIONAL",[193],"PHASE3","The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.",[196,197,198,199,200,201],"Epithelial Ovarian Carcinoma Stage III","Epithelial Ovarian Carcinoma Stage IV","Fallopian Tube Carcinoma Stage III","Fallopian Tube Carcinoma Stage IV","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV","2025-02-09",{"date":204,"type":205},"2025-02-11","ACTUAL",{"date":207,"type":205},"2023-11-27",{"date":209,"type":190},"2027-12-31",{"name":5,"class":6},11]